A Single-centre, Parallel-cohort, Open-label Study to Assess the Food Effect and Multiple Dose Pharmacokinetic of the HR20033in Healthy Chinese Subjects
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Henagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Shandong Suncadia Medicine
- 22 Nov 2021 Planned End Date changed from 20 Nov 2021 to 20 Dec 2021.
- 22 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2021 New trial record